Integriertes Kompetenzzentrum für Arzneimittelforschung in der Onkologie

Boehringer Ingelheim Regional Center Vienna (RCV) ist das globale Krebsforschungszentrum im Unternehmensverband sowie das Center of Excellence für die Forschung, Entwicklung und Produktion von Biopharmazeutika in mikrobiellen Systemen. Damit zählt das Boehringer Ingelheim RCV zu den bedeutendsten forschenden Pharmaunternehmen im österreichischen Life-Science-Bereich.

Schlagworte

Website

http://www.boehringer-ingelheim.at

A Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma in Biomarker-Selected Patients

Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of B cell lymphoma. DLBCL patients have limited treatment options and are frequently refractory after standard therapy. The aim of this project is to develop a new therapeutic treatment option for DLBCL patients. A transcriptional repressor and regulator of apoptosis and proliferation in B cells, which in DLBCL acts as a key oncogene through genetic mutations or transcriptional deregulation, was selected as molecular target. Small molecule compounds will be designed which specifically disrupt the oncogenic function of the target, and their efficacy tested against tumour growth on cultured human DLBCL cells as well as in animal models. In-depth studies will be performed to determine biomarkers identifying those patients most likely benefiting from compound treatment. The cumulative results from biological and pharmaceutical approaches in combination with a clear patient stratification and biomarker strategy will enable the generation of a highly efficient, first in class compound for patients with DLBCL.

Alleinstellungsmerkmal

.